Pharmacotherapy of somatoform disorders

Journal of Psychosomatic Research

Volumn 56, Issue 4, 2004, Pages 455-460

  Fallon, Brian A ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Body dysmorphic disorder; Hypochondriasis; Pharmacotherapy; Serotonin reuptake inhibitors; Somatization; Somatoform

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LAMOTRIGINE; MAPROTILINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRAZODONE; VENLAFAXINE;

BODY DYSMORPHIC DISORDER; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HYPOCHONDRIASIS; MEDLINE; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PAIN; REVIEW; SOMATIZATION; SOMATOFORM DISORDER; TREATMENT OUTCOME;

EID: 1842839803     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3999(03)00631-7     Document Type: Article

References (40)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4th ed:1994;American Psychiatric Association, Washington, DC.
2. Kellner R. Hypochondriasis and somatization. JAMA. 258:1987;2718-2722.
3. Fallon B.A., Javitch J.A., Hollander E., Liebowitz M.R. Hypochondriasis and obsessive - compulsive disorder; overlaps in diagnosis and treatment. J Clin Psychiatry. 52:1991;457-460.
4. Hollander E., Cohen L.J., Simeon D. Obsessive compulsive spectrum disorders: body dysmorphic disorder. Psychiatric Ann. 23:1993;359.
5. Kellner R., Fava G.A., Lisansky J., Perini G.I., Zielezny M. Hypochondriacal fears and beliefs in DSM-III melancholia: changes with amitriptyline. J Affect Disord. 10:1986;21-26.
6. Noyes R., Reich J., Clancy J., O'Gorman T.W. Reduction in hypochondriasis with treatment of panic disorder. Br J Psychiatry. 149:1986;631-635.
7. Nemiah J.C. Hypochondriasis. Kaplan H.I., Sadock B.J. Comprehensive textbook of psychiatry. 4th ed:1985;937-942 Williams and Wilkins, Baltimore, MD.
8. Kamlana S.H., Gray P. Fear of AIDS (letter). Br J Psychiatry. 15:1988;1291.
9. Stone A.B. Treatment of hypochondriasis with clomipramine (letter). J Clin Psychiatry. 54:1993;5.
10. Fallon B.A., Schneier F.R., Marshall R., Campeas R., Vermes D., Goetz D., Liebowitz M.R. The pharmacotherapy of hypochondriasis. Psychopharm Bull. 32:1996;607-611.
11. Viswanathan R., Paradis C. Treatment of cancer phobia with fluoxetine. Am J Psychiatry. 148:1991;1090.
12. Fallon B.A., Javitch J.A., Hollander E., Liebowitz M.R. Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. J Clin Psychiatry. 52:1991;457-460.
13. Fallon B.A., Feinstein S. Hypochondriasis. Phillips K.A. Somatoform and factitious disorders. 2001;27-65 American Psychiatric Publishing, Washington, DC. review of Psychiatry Series, Vol. 20, No. 3; Oldham JM and Riba MB, series editors.
14. Fallon B.A., Liebowitz M.R., Salmon E., Schneier F.R., Jusino C., Hollander E., Klein D.F. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol. 13:1993;438-441.
15. Fallon B.A., Qureshi A.I., Schneier F.R., Sanchez-Lacay A., Vermes D., Feinstein R., Connelly J., Liebowitz M.R. An open trial of fluvoxamine for hypochondriasis. Psychosomatics. 44:2003;298-303.
16. Oosterbaan D.V., van Balkom A.J., van Boeijen C.A., de Meji T.G., van Dyck R. An open study of paroxetine in hypochondriasis. Prog Neuropsychopharmacol Biol Psychiatry. 25:2001;1023-1033.
17. Kjernisted K.D., Enns M.W., Lander M. An open-label clinical trial of nefazodone in hypochondriasis. Psychosomatics. 43:2002;290-294.
18. Wesner R.B., Noyes R. Imipramine: an effective treatment for illness phobia. J Affect Disord. 22:1992;43-48.
19. Fallon B.A. Pharmacotherapy of hypochondriasis. International Congress on Somatoform Disorders, Marburg, Germany:2002;. Feb.
20. Hollander E., Liebowitz M.R., Winchel R., Limker A., Klein D.F. Treatment of BDD with serotonin reuptake blockers. Am J Psychiatry. 146:1989;768-770.
21. Phillips K.A., Dwight M.M., McElroy S.L. Efficacy and safety of fluvoxamine in BDD. J Clin Psychiatry. 59:1988;165-171.
22. Phillips K.A., McElroy S.L., Dwight M.M., Eisen J.L., Rasmussen S.A. Delusionality and response to open-label fluvoxamine in BDD. J Clin Psychiatry. 62:2001;87-91.
23. Phillips K.A. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacol Bull. 32:1996;597-605.
24. Hollander E., Allen A., Kwon J., Aronowitz B., Schmeidler J., Wong C., Simeon D. Clomipramine vs desipramine crossover trial in BDD: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 56:1999;1033-1039.
25. Phillips K.A., Albertini R.S., Rasmussen S.A. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 59:2002;381-388.
26. Escobar J.I., Rubio-Stipec M., Canino G., Karno M. Somatic Symptom Index (SSI); a new and abridged somatization construct. J Nerv Ment Dis. 177:1989;140-146.
27. Noyes R., Happel R., Muller B., Holt C.S., Kathol R.G., Sieren L., Amos J. Fluvoxamine for somatoform disorders: an open trial. Gen Hosp Psychiatry. 20:1998;339-344.
28. Cannon R.O. The sensitive heart: a syndrome of abnormal cardiac pain perception. JAMA. 273:1995;883-887.
29. Davidson J., Raft D., Pelton J. An outpatient evaluation of phenelzine and imipramine. J Clin Psychiatry. 48:1987;143-146.
30. Onghena P., Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 49:1992;205-219.
31. Krishnan K.R.R. Monoamine oxidase inhibitors. Schatzberg A.F., Nemeroff C.B. Textbook of psychopharmacology. 1995;239-250 American Psychiatric Press, Washington, DC.
32. Max M.B., Lynch S.A., Muir J., Shoaf S.E., Smoller B., Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 326:1992;1250-1256.
33. Tollefson G.D. Selective serotonin reuptake inhibitors. Schatzberg A.F., Nemeroff C.B. Textbook of psychopharmacology. 1995;219-238 American Psychiatric Press, Washington, DC.
34. Zitman F.G., Linssen A.C.G., Edelbroek P.M., Van Kempen G.M.J. Does addition of low-dose flupenthixol enhance the analgesic effects of low-dose amitriptyline in somatoform pain disorder? Pain. 47:1991;25-30.
35. Sindrup S.H., Bach F.W., Madsen C., Gram L.F., Jensen T.S. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 60:2003;1284-1289.
36. Semenchuck M.R., Sherman S., Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 57:2001;1583-1588.
37. Backonja M. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 59:2002;S14-S17.
38. Fallon B.A. Pharmacologic strategies for hypochondriasis. Starcevic V., Lipsitt D.R. Hypochondriasis: modern perspectives on an ancient malady. 2001;329-351 Oxford University Press, New York.
39. Noyes R., Kathol R.G., Fisher M.M., Phillips B.M., Suelzer M.T., Woodman C.L. One-year follow-up of medical outpatients with hypochondriasis. Psychosomatics. 35:1994;533-545.
40. Fallon B.A. Somatoform disorders. Feinstein R.E., Brewer A.A. Primary care psychiatry and behavioral medicine: brief office treatment and management pathways. 1999;146-170 Springer, NY.